Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK provides update on Herpevac trial for women evaluating Simplirix™ (Herpes Simplex Vaccine)
GSK has made the decision not to pursue further worldwide development of Herpes Simplex Vaccine.
-
GlaxoSmithKline receives EU approval for a new therapeutic indication for Arixtra® (fondaparinux)
GSK confirmed today that the European Commission has granted an amendment of their marketing authorisation for their anti-clotting agent.
-
GSK regulatory update on Avandia following EMA and FDA reviews
GSK confirms that following a review of Avandia® (rosiglitazone maleate) by the EMA and the FDA.
-
GSK EU regulatory update on Pandemrix™
GSK confirmed that on behalf of the EMA, CHMP has concluded that the available data are insufficient to Pandemrix and narcolepsy.
-
GSK and Theravance announce combination ICS/LABA Phase II results in the Relovair™ development programme
Additional data presentations for fluticasone furoate and vilanterol trifenatate support the potential developmental combination treatment
-
GlaxoSmithKline and Genmab refocus development programme for ofatumumab in autoimmune indications
GSK and Genmab announced today plans to refocus the development programme of ofatumumab in autoimmune indications.
-
Three-year results from ECLIPSE study indicate that COPD patients may require prevention strategies to manage exacerbations, regardless of disease severity
Today the New England Journal of Medicine published results from ECLIPSE, an extensive research programme sponsored by GSK.
-
GSK and BJD collaborate on a new educational programme to reduce global burden of joint pain
BJD international initiative and GSK today announced the launch of the LIBERATE™ joint pain management programme.
-
Audio recording of meeting between GSK and Dr Nissen to discuss Avandia
Audio recording of meeting between GSK and Dr Nissen to discuss Avandia
-
GlaxoSmithKline and Genmab announce start of ofatumumab Phase III combination study in non-Hodgkin’s lymphoma
GSK and GEN announced today the start of a Phase III study in patients with indolent B-cell non-Hodgkin’s lymphoma (B-NHL).
-
GSK announces succession plan for Chief Financial Officer
GSK announces that Julian Heslop is to retire as Chief Financial Officer and Executive Director of the company at the end of March 2011.
-
Galapagos reaches agreement to acquire GlaxoSmithKline research centre in Zagreb, Croatia
R&D operations in Zagreb fulfil Galapagos; growing R&D capacity requirements
-
GSK signs agreement with Lonza to secure capacity and expertise in biological manufacturing to support ongoing development of GSK’s biopharmaceuticals portfolio
GSK and Lonza today announced that they have entered into a new agreement under which Lonza will support the ongoing development of GSK.
-
BBC Panorama – 6 September 2010
Patient safety is our first priority. We strongly refute any allegation that our actions have put patients at risk.
-
GlaxoSmithKline pre-broadcast statement: BBC Panorama, 6 September 2010
GSK today issued the statement in anticipation of the BBC programme, A risk worth taking which is scheduled to be aired this evening.
-
GlaxoSmithKline responds to British Medical Journal article regarding Avandia® (rosiglitazone)
GSK continues to work in the best interest of diabetes patients who face this chronic and serious disease.
-
Reports of narcolepsy in Europe following vaccination with Pandemrix™
GSK became aware of cases of narcolepsy following vaccination with the adjuvanted H1N1 pandemic vaccine Pandemrix.
-
GSK and Valeant announce new U.S. FDA PDUFA goal date for ezogabine
GSK and VRX announced today FDA has extended the PDUFA goal date for ezogabine* to 30 Nov 2010, the original goal date was 30 August 2010.
-
GSK commences Phase III clinical trials to develop herpes zoster vaccine for the prevention of shingles
GSK confirmed that the company has commenced the Phase III clinical trials programme of its candidate herpes zoster vaccine.
-
GlaxoSmithKline and Human Genome Sciences announce FDA priority review designation for Benlysta® (belimumab) as a potential treatment for systemic lupus erythematosus
GSK and Human Genome Sciences, Inc. today announced that the FDA has granted a priority review designation to Benlysta.
